Low pretransplant bone-mineral density and rapid bone loss do not increase risk for avascular osteonecrosis after allogeneic hematopoietic stem cell transplantation

被引:11
|
作者
Schulte, CMS [1 ]
Beelen, DW [1 ]
机构
[1] Univ Hosp Essen, Dept Bone Marrow Transplant, D-45122 Essen, Germany
关键词
avascular osteonecrosis; bone-mineral density; bone loss; risk-factor analysis; stem cell transplantation;
D O I
10.1097/01.TP.0000164353.86447.DB
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Avascular osteonecrosis (AVN) is a serious complication of allogeneic stem cell transplantation (SCT). Graft-versus-host disease and its treatment with steroids are the main risk factors; underlying diagnosis, age and gender are further risk factors. It has been speculated that low baseline bone mineral density (BMD) is associated with AVN posttransplant. Furthermore, rapid bone loss with consecutive microarchitectural changes might prone patients to AVN. Methods. In a single-center prospective cohort study, 255 patients undergoing allogeneic SCT for CML, AML, MDS, and ALL were followed for at least 5 years. We measured BMD (spine, femoral neck, total body) and body indices (body weight, body mass index, body composition determined by dual-energy x-ray absorptiometry) at baseline. Annual changes of BMD and body indices were prospectively observed for 5 years. Incidence of hip AVN necessitating total arthroplasty (severe adverse event) was determined. Univariate and multifactorial nominal logistic as well as Cox proportional hazard analysis were performed. Results. Severe adverse events occurred in nine patients (5-year cumulative incidence rate 6.9%). Baseline BMD and body indices were within normal limits. Rapid and intense bone loss occured, especially during the first year, accompanied by loss of body and especially muscle mass. AVN occurrence was not associated with BMD or body indices at baseline neither with prospectively observed changes of BMD or body indices. Conclusions. AVN is a devastating frequent complication of allogeneous SCT. Allogeneous SCT is followed by dramatic changes in BMD and body composition. However, low BMD and rapid bone loss per se do not dispose patients to AVN occurrence.
引用
收藏
页码:1748 / 1755
页数:8
相关论文
共 50 条
  • [31] Risk Factors for Hematopoietic Stem Cell Transplantation-Associated Bone Loss
    Khan, Zehva
    Agarwal, Nidhi B.
    Bhurani, Dinesh
    Khan, Mohd Ashif
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03): : 212 - 221
  • [32] Late Donor Bone Marrow Failure After Allogeneic Hematopoietic Stem Cell Transplantation
    Meunier, Mathieu
    Manez, Anne-Claire
    Xhaard, Alienor
    de Latour, Regis Peffault
    de Fontbrune, Flore Sicre
    Dhedin, Nathalie
    Socie, Gerard
    Robin, Marie
    TRANSPLANTATION, 2014, 97 (12) : E75 - E77
  • [33] Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation
    Masouridi-Levrat, Stavroula
    Simonetta, Federico
    Chalandon, Yves
    FRONTIERS IN IMMUNOLOGY, 2016, 7
  • [34] POPULATION SCREENING FOR LOW BONE-MINERAL DENSITY - DO NONATTENDERS HAVE A LOWER RISK OF OSTEOPOROSIS
    TORGERSON, DJ
    DONALDSON, C
    GARTON, MJ
    RUSSELL, IT
    WESTLAND, M
    REID, DM
    OSTEOPOROSIS INTERNATIONAL, 1994, 4 (03) : 149 - 153
  • [35] Prospective Assessment of Bone Turnover and Clinical Bone Diseases After Allogeneic Hematopoietic Stem-Cell Transplantation
    Petropoulou, Anna D.
    Porcher, Raphael
    Herr, Andree-Laure
    Devergie, Agnes
    Brentano, Thomas Funck
    Ribaud, Patricia
    Pinto, Fernando O.
    Rocha, Vanderson
    de Latour, Regis Peffault
    Orcel, Philippe
    Socie, Gerard
    Robin, Marie
    TRANSPLANTATION, 2010, 89 (11) : 1354 - 1361
  • [36] DECLINE IN BONE MINERAL DENSITY IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: IMPACT OF MYELOABLATIVE VERSUS REDUCED INTENSITY CONDITIONING REGIMENS
    McCullough, K. B.
    Burzynski, J. A.
    Hogan, W. J.
    Litzow, M. R.
    Wolf, R. C.
    Wermers, R. A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S353 - S354
  • [37] Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation
    Ria, Roberto
    Scarponi, Anna Maria
    Falzetti, Franca
    Ballanti, Stelvio
    Di Ianni, Mauro
    Sportoletti, Paolo
    Cimminiello, Michele
    Gasbarrino, Cristiana
    Pallone, Benedetta
    Vacca, Angelo
    Dammacco, Franco
    Mannarino, Elmo
    Tabilio, Antonio
    LEUKEMIA & LYMPHOMA, 2007, 48 (05) : 923 - 930
  • [38] AVASCULAR BONE NECROSIS: HIGH MORBIDITY AND IMPACT ON QUALITY OF LIFE IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION SURVIVORS
    Uria Oficialdegui, Maria Luz
    Panesso, Melissa
    Martinez, Laia
    Isabel Benitez-Carabante, M.
    Pacha, Daniel
    Riera, Luis
    Alonso, Laura
    Campos, Ariadna
    Velasco, Pablo
    Llort, Anna
    Marsal Barril, Sara
    Lopez-Corbeto, Mireia
    Diaz-de-Heredia, Cristina
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 544 - 544
  • [39] Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation
    D'Souza, A. B.
    Grigg, A. P.
    Szer, J.
    Ebeling, P. R.
    INTERNAL MEDICINE JOURNAL, 2006, 36 (09) : 600 - 603
  • [40] Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation
    Tauchmanovà, L
    De Simone, G
    Musella, T
    Orio, F
    Ricci, P
    Nappi, C
    Lombardi, G
    Colao, A
    Rotoli, B
    Selleri, C
    BONE MARROW TRANSPLANTATION, 2006, 37 (01) : 81 - 88